HERON THERAPEUTICS, INC. /DE/
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
HRTX$0.37+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders' Equity (Deficit)
| Series A · Accumulated | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Convertible · Additional · Other · Total | |||||||||
| Common Stock · Preferred Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | |||||||||
| Shares · Amount · Shares · Amount · Capital · (Loss) Income · Deficit · Equity | |||||||||
| Balance as of December 31, 2025 | 188,314 | $1,883 | 70 | $1,050 | $1,951,185 | $4 | $(1,939,789) | $14,333 | |
| Issuance of common stock under equity incentive plan | 262 | 3 | — | — | (54) | — | — | (51) | |
| Stock-based compensation expense | — | — | — | — | 2,976 | — | — | 2,976 | |
| Net loss | — | — | — | — | — | — | (8,111) | (8,111) | |
| Net unrealized loss on short-term investments | — | — | — | — | — | (10) | — | (10) | |
| Comprehensive loss | (8,121) | ||||||||
| Balance as of March 31, 2026 (unaudited) | 188,576 | 1,886 | 70 | 1,050 | 1,954,107 | (6) | (1,947,900) | 9,137 | |
| Issuance of common stock under equity incentive plan | 654 | 7 | — | — | (150) | — | — | (143) | |
| Issuance of common stock under the employee stock purchase plan | 229 | 2 | — | — | 223 | — | — | 225 | |
| Stock-based compensation expense | — | — | — | — | 3,178 | — | — | 3,178 | |
| Net loss and comprehensive loss | — | — | — | — | — | — | (5,489) | (5,489) | |
| Balance as of June 30, 2026 (unaudited) | 189,459 | $1,895 | 70 | $1,050 | $1,957,358 | $(6) | $(1,953,389) | $6,908 | |
| Series A · Accumulated | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Convertible · Additional · Other · Total | ||||||||||
| Common Stock · Preferred Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | ||||||||||
| Shares · Amount · Shares · Amount · Capital · (Loss) Income · Deficit · (Deficit) | ||||||||||
| Balance as of December 31, 2024 | 152,128 | $1,521 | — | $— | $1,884,409 | $13 | $(1,919,594) | $(33,651) | ||
| Issuance of common stock under equity incentive plan | 299 | 3 | — | — | 61 | — | — | 64 | ||
| Stock-based compensation expense | — | — | — | — | 2,511 | — | — | 2,511 | ||
| Net income | — | — | — | — | — | — | 2,635 | 2,635 | ||
| Net unrealized loss on short-term investments | — | — | — | — | — | (12) | — | (12) | ||
| Comprehensive income | 2,623 | |||||||||
| Balance as of March 31, 2025 (unaudited) | 152,427 | 1,524 | - | - | 1,886,981 | 1 | (1,916,959) | (28,453) | ||
| Issuance of common stock under equity incentive plan | 438 | 5 | — | — | 189 | — | — | 194 | ||
| Issuance of common stock under the employee stock purchase plan | 388 | 4 | — | — | 583 | — | — | 587 | ||
| Stock-based compensation expense | — | — | — | — | 2,797 | — | — | 2,797 | ||
| Net loss | — | — | — | — | — | — | (2,381) | (2,381) | ||
| Net unrealized loss on short-term investments | — | — | — | — | — | (2) | — | (2) | ||
| Comprehensive loss | (2,383) | |||||||||
| Balance as of June 30, 2025 (unaudited) | 153,253 | $1,533 | — | $ | - | $1,890,550 | $(1) | $(1,919,340) | $(27,258) | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.